Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.
Actively Recruiting
Researchers are evaluating treatment options for patients aged 70 and older with metastatic non-small cell lung cancer NSCLC who have lower than 50% PD-L1 expression and may be frail or in poor health. The study aims to compare the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. This research addresses a gap in evidence for older and frail patients who often cannot tolerate standard chemotherapy doses well. Participants are randomly assigned to one of two groups one receives reduced-dose platinum-doublet chemotherapy combined with cemiplimab, while the other receives cemiplimab monotherapy. The chemotherapy regimens differ according to cancer histology and are given intravenously every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years. Patients whose cancer progresses may switch from monotherapy to the combination treatment if suitable. Throughout the study, participants undergo regular imaging scans to assess tumor response every 6 to 12 weeks, along with quality-of-life questionnaires and geriatric assessments of physical function at set intervals. Researchers will monitor progression-free survival, overall survival, response rates, side effects, and overall treatment utility. The trial includes ongoing safety monitoring and aims to provide evidence to improve treatment strategies for older, vulnerable NSCLC patients.
Actively Recruiting
This research project involves collecting biological samples and health-related medical data to study Primary Biliary Cholangitis PBC, a rare liver disease. It aims to gather high-quality prospective data to better understand the diseases epidemiology, natural history, treatment response, and outcomes. The study also plans to use already existing coded medical data for further research and will collaborate with international PBC reference networks. Participants will have an enrollment visit and at least one follow-up visit annually. Each year, a blood sample will be collected for biobanking. When available and collected during routine clinical care, liver tissue samples may also be obtained. These procedures support ongoing research into various scientific questions about PBC. During the study, researchers will monitor disease progression, features, treatment responses, overall survival, and transplantation-free survival over three years. Participants health data and biological samples will be used to explore these outcomes. The total participation duration includes initial enrollment and yearly follow-ups, allowing for long-term observation and data collection.
Actively Recruiting
This research collects biological samples and health-related personal data from people with Primary Sclerosing Cholangitis PSC, a rare liver disease. The goal is to better understand the diseases occurrence, natural progression, how patients respond to treatments, and outcomes over time. The study also aims to support scientific research and collaborations with other PSC networks internationally. Participants provide biological material to build a biobank, which helps researchers explore specific scientific questions about PSC. The study does not involve specific treatments but gathers detailed information and samples to advance knowledge about the disease. During the study, researchers collect and analyze coded health data and biological samples from participants. They will monitor disease course, features, treatment responses, overall survival, and transplant-free survival over three years. The study provides a platform for ongoing research and collaboration, with no set end to participation beyond data collection and follow-up.
Actively Recruiting
Researchers are evaluating the safety and effects of stopping systemic glucocorticoid treatment quickly compared to gradually reducing the dose over 4 weeks in patients with inflammatory or autoimmune disorders. This trial is a placebo-controlled, multicenter, randomized study designed to compare rapid termination with a tapering regimen of prednisone. It aims to determine if abrupt stopping is not worse than tapering in terms of patient outcomes over six months. Participants will be randomly assigned to one of two groups one group will receive prednisone with decreasing doses over 4 weeks following a specific tapering schedule, while the other group will stop glucocorticoid treatment abruptly and receive a matching placebo over the same period. Both patients and study staff will be unaware of the treatment allocation. The trial includes a stimulation test at the start, and patients will receive education on managing stress and symptoms related to low cortisol. Follow-up visits will occur mostly by phone at days 7, 35, 90, and 180 to ensure safety and monitor progress. During the study, participants will be monitored for time to any incidence related to glucocorticoid withdrawal up to 6 months, with additional outcomes including health status, symptoms of low cortisol, and hospital stay length if applicable. Safety is a priority with early visits after stopping treatment and emergency medication provided. Researchers will also assess test performance and glucocorticoid doses taken for relapse or adrenal failure treatment. The total follow-up duration for participants is six months.